跳转至内容
Merck

M-106

Supelco

霉酚酸标准液 CRM 溶液

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C17H20O6
CAS号:
分子量:
320.34
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

certified reference material

品質等級

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商/商標名

Cerilliant®

濃度

1.0 mg/mL in acetonitrile

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

clinical testing

形式

single component solution

儲存溫度

−70°C

SMILES 字串

COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O

InChI

1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+

InChI 密鑰

HPNSFSBZBAHARI-RUDMXATFSA-N

基因資訊

一般說明

在治疗药物监测中进行分析,以确保患者保持在药物治疗范围内,霉酚酸是一种免疫抑制药物,也是前药霉酚酸酯的活性代谢物。本分析标准适用于 LC-MS/MS 应用,包括治疗药物监测和其他临床或诊断应用。

應用


  • 胃肠道毒性的靶向抑制:研究人员将霉酚酸用于肠道细菌中葡萄糖醛酸酶的靶向抑制研究,用于减轻麦考酚酸酯引起的胃肠道毒性。该应用对于我们改善免疫抑制治疗的病人恢复结果至关重要,体现了其在药物研究中的价值(Xia et al., 2024)。

  • 协同免疫抑制疗法:该溶液可以与低剂量全身性免疫抑制治疗一起使用来维持血管化复合同种异体移植物(vascularized composite allograft )的存活率,该应用突显了其在移植医学中的潜力。这项研究强调了霉酚酸在有效免疫抑制方案制定中的关键作用(Feturi et al., 2024).

  • 遗传标记物的开发:研究人员将霉酚酸的生化特性用于开发解脂耶氏酵母的遗传标记物,研究证明了其在基因工程和生物技术发展中的重要性(Zhu et al., 2024)。

  • 杀菌化合物的发现:该化合物可用于从芥子酸和霉酚酸中获取杀菌性酰肼先导化合物,研究阐明了其在农业生物化学和新型抗菌剂开发中的应用(Fang et al., 2023)。

準備報告

本品含有 1 mL 安瓿,浓度为 1.0 mg/mL 的乙腈溶液。

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

象形圖

FlameExclamation mark

訊號詞

Danger

危險分類

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Eye Irrit. 2 - Flam. Liq. 2

儲存類別代碼

3 - Flammable liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

35.6 °F - closed cup

閃點(°C)

2 °C - closed cup


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

David Wofsy et al.
Arthritis and rheumatism, 65(6), 1586-1591 (2013-03-27)
Clinical trials of therapies for lupus nephritis have used many different primary outcome measures, ranging from complete response to time to end-stage renal disease. The objective of this study was to compare several possible outcome measures, using data from a
CD25 blockade for refractory polymyositis.
Nicolò Pipitone et al.
Clinical and experimental rheumatology, 31(3), 474-474 (2013-03-08)
Mycophenolate mofetil in severe lupus nephritis: should post hoc analyses change treatment patterns?
Jonathan J Hogan et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 61(5), 692-693 (2013-04-16)
Nathan R Selden et al.
Journal of neurosurgery. Pediatrics, 11(6), 643-652 (2013-04-16)
Infantile and late-infantile neuronal ceroid lipofuscinoses (NCLs) are invariably fatal lysosomal storage diseases associated with defects in lysosomal enzyme palmitoyl-protein thioesterase 1 (PPT-1) or tripeptidyl peptidase 1 (TPP1) activity. Previous preclinical studies have demonstrated that human CNS stem cells (HuCNS-SCs)
Yutaro Mori et al.
Nihon Jinzo Gakkai shi, 55(2), 177-184 (2013-05-02)
A 26-year-old man diagnosed with nephrotic syndrome was administered steroid monotherapy. Urinary protein excretion was 2-3 g/day despite the therapy. Percutaneous renal biopsy revealed Type I idiopathic membranoproliferative glomerulonephritis (IMPGN). Although intravenous steroid therapy at the dose of 1,000 mg/day

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门